Actualités et Activités de Lexicon Pharmaceuticals
Présence
Lexicon Pharmaceuticals fait partie des...
Lexicon Pharmaceuticals est une société cotée sous le symbole boursier LXRX (US).
Dirigeants
Voir l'organigramme avec ses 30 principaux dirigeants
Biographies les plus recherchées chez Lexicon Pharmaceuticals
- Mike Exton, Chief Executive Officer and Director
- Raymond Debbane, Chairman of the Board
- Diane Sullivan, Director
Changements de dirigeants chez Lexicon Pharmaceuticals
- Scott Coiante, a rejoint l'entreprise comme Chief Financial Officer (publié le 2 janvier 2025).
- Robert Lefkowitz, qui est Director, part en retraite (publié le 21 novembre 2024).
- Ivan Cheung, a rejoint l'entreprise comme Director (publié le 21 novembre 2024).
Cliquez ici pour voir d'autres changements chez Lexicon Pharmaceuticals
Créer une alerte
pour suivre les mouvements de dirigeants chez Lexicon Pharmaceuticals.
Biotechnologie
Lexicon Pharmaceuticals a 2 339 concurrents dont Eurofins (Luxembourg), Lonza (Suisse) et Biogen (Etats—Unis).
Actualités en fusion/acquisition en Biotechnologie.
- Jade Biosciences and Aerovate Therapeutics have announced they will merge (publié le 30 avril 2025)..
- Deepull vient d'annoncer une levée de fonds de 50 millions de dollars. (publié le 29 avril 2025).
- Biolinq vient d'annoncer une levée de fonds de 100 millions de dollars. (publié le 23 avril 2025).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Lexicon Pharmaceuticals
- Lexicon Reveals “into the Dark” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization | Lexicon Pharmaceuticals, Inc.Lexicon Reveals “into the Dark” Awareness Campaign About Vulnerable a
- New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Heart Federation’s World Congress of Cardiology | Lexicon Pharmaceuticals, Inc.New Analyses
- Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
- Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023 | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2,
- New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Heart Federation’s World Congress of Cardiology | Lexicon Pharmaceuticals, Inc.New Analyses of Sotagliflozin to Be Pre
- Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference
- Lexicon Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia | Lexicon Pharmaceuticals, Inc.Lexicon Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia
- Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Heal
- Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results from the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit | Lexicon Pharmaceuticals, Inc.Lexicon’s L
- Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Lexicon Pharmaceuticals
- Lexicon Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Lexicon Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
